Print

AVEG 013B

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) January 23, 1995
gp160 Vaccine (Immuno-AG) Protein gp160 env B LAI, MN
gp160 Vaccine (Immuno-AG) Protein
USA 20
NCT00001043
https://clinicaltrials.gov/show/NCT00001043